Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 9, 2017 in Breast cancer | 0 comments

In a nutshell

This study set out to evaluate heart function in patients who received traustuzumab with anthracycline and taxanebased chemotherapy. This study concluded that, in patients without heart disease at baseline, adding traustuzumab to adjuvant anthracycline and taxanebased chemotherapy does not worsen heart function or health-related quality of life long-term. 

Some background

Breast cancer is classified into different subtypes depending on the presence or absence of certain receptors (proteins found on the surface of the cancer cells). Human epidermal growth factor receptor 2 (HER-2) is a receptor that is targeted by trastuzumab (Herceptin)Anthracycline and taxanebased chemotherapy (such as doxorubicin, cyclophosphamide, and paclitaxol) is used with or without trastuzumab for adjuvant treatment of lymph node positive and HER-2 positive early breast cancer. 

It is unclear what long-term effect this combined chemotherapy regime and trastuzumab has on heart function. 

Methods & findings

441 patients were included in this study and were followed for 8.8 years. Heart function and quality of life were monitored using questionnaires. 

There were no significant changes to long-term heart function or quality of life with the addition of trastuzumab. 

The bottom line

This study concluded that, in patients without heart disease at baseline, adding trastuzumab to adjuvant anthracycline and taxane-based chemotherapy does not worsen heart function or health related quality of life long-term.

The fine print

The median age of participants in this study was 50 years, which could impact on results. 

Published By :

Journal of clinical oncology

Date :

Oct 26, 2017

Original Title :

Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitax

click here to get personalized updates